| Clearview Wealth Limited (CVW) ORDINARY FULLY PAID |
Financials |
$417 |
Court Approves Scheme
|
30 Jul 2026 10:50AM |
$0.648 |
$0.650 |
risen by
0.39%
|
|
CVW - Price-sensitive ASX Announcement
Full Release
Key Points
- Supreme Court of New South Wales approves the scheme of arrangement for Zurich to acquire ClearView.
- The scheme becomes effective upon court order lodgment with ASIC on 31 July 2026.
- ClearView shares will be suspended from trading on the ASX after 31 July 2026.
- Shareholders will receive A$0.60 per share in cash on 20 August 2026.
- A special dividend of A$0.05 per share will be paid on 12 August 2026.
- Special dividend payment is contingent on the scheme becoming effective.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SHAPE Australia Corporation Limited (SHA) ORDINARY FULLY PAID |
Industrials |
$557 |
FY26 Results Notification & Webinar Details
|
30 Jul 2026 10:48AM |
$6.420 |
$6.640 |
risen by
3.43%
|
|
| Pantoro Gold Limited (PNR) ORDINARY FULLY PAID |
Materials |
$978 |
Quarterly Results Presentation
|
30 Jul 2026 10:48AM |
$1.978 |
$2.510 |
risen by
26.93%
|
|
| Terragen Holdings Limited (TGH) ORDINARY FULLY PAID |
Materials |
$16 |
Appendix 4C - 30 June 2026
|
30 Jul 2026 10:47AM |
$0.020 |
$0.019 |
fallen by
5%
|
|
TGH - Price-sensitive ASX Announcement
Full Release
Key Points
- Terragen Holdings Limited executed a supply agreement with Mort & Co.
- The Ravensworth Feedlot Supply Agreement includes a minimum order of 360,000 doses of TPR.
- Sales of TPR have the potential to increase to 160,000 head of beef cattle in CY2027.
- Appendix 4C details financials including cash flows, with a reported net cash used in operating activities of $3,378,000 for the year.
- Terragen has a new national supply agreement with Nutrien Ag Solutions Australia.
- Winter Cropping Trials Program aims to improve nutrient use efficiency and crop resilience.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Challenger Gold Limited (CEL) ORDINARY FULLY PAID |
Materials |
$477 |
First Exploration Drilling in 3 Years Underway at Hualilan
|
30 Jul 2026 10:46AM |
$2.240 |
$2.800 |
risen by
25%
|
|
CEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Challenger Gold Limited (ASX: CEL) announced the commencement of exploration drilling at Hualilan for the first time in over three years.
- The drilling program includes a minimum of 35,000 meters of diamond drilling, with 5,000 meters dedicated to geotechnical drilling for Phase 1 Heap Leach project development.
- The program targets exploration drilling to test mineralisation extensions and conversion within the existing open pit design.
- A comprehensive review of geophysical datasets is underway to support exploration across the Hualilan property.
- Challenger Gold's strategy includes unlocking value through disciplined, technically driven exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID |
Health Care |
$115 |
U.S. Government Releases US$66.9B AMR Biodefense Strategy
|
30 Jul 2026 10:38AM |
$0.375 |
$0.375 |
fallen by
0%
|
|
| MinRex Resources Limited (MRR) ORDINARY FULLY PAID |
Materials |
$34 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jul 2026 10:35AM |
$0.016 |
$0.016 |
fallen by
0%
|
|
MRR - Price-sensitive ASX Announcement
Full Release
Key Points
- MinRex released its 2026 Growth & Execution Plan.
- Drilling commenced at Barje Deposit in Tlamino Gold Project.
- Expansion and exploration efforts in Serbia and Australia.
- Cash and cash equivalents stood at $6.04 million.
- No financing facilities were drawn during the quarter.
- The company strengthened its leadership team with new appointments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Navigator Global Investments Limited (NGI) FPO-U.S. INVESTOR PROHIBITED EXCEPT QPS |
Financials |
$1,635 |
2026 Annual Results Briefing Details
|
30 Jul 2026 10:19AM |
$2.360 |
$2.680 |
risen by
13.56%
|
|
| Macquarie Group Limited (MQG) ORDINARY FULLY PAID |
Financials |
$100,381 |
Notification of cessation of securities - MQG
|
30 Jul 2026 10:18AM |
$250.310 |
$261.660 |
risen by
4.53%
|
|
| Macquarie Group Limited (MQG) ORDINARY FULLY PAID |
Financials |
$100,381 |
Notification regarding unquoted securities - MQG
|
30 Jul 2026 10:17AM |
$250.310 |
$261.660 |
risen by
4.53%
|
|
| DataWorks Group Limited (DWG) ORDINARY FULLY PAID |
Information Technology |
$16 |
Appendix 4C & Quarterly Activities Report
|
30 Jul 2026 10:17AM |
$0.120 |
$0.160 |
risen by
33.33%
|
|
DWG - Price-sensitive ASX Announcement
Full Release
Key Points
- Dataworks Group Limited (ASX: DWG) generated positive operating cashflow of approximately $276,000 for FY26, achieving cashflow breakeven.
- The company reported positive operating cashflow of approximately $538,000 during the June quarter.
- Customer cash receipts increased to over $10.3 million during FY26, rising to approximately $11.1 million after including the R&D tax incentive.
- Dataworks launched BetGuard, Ontario's Centralised Self-Exclusion platform, and established a dedicated Toronto-based Contact Centre.
- The company's platforms have processed over 41 billion real-time exclusion checks globally.
- Dataworks completed the largest contract expansion through the Ontario Change Order.
- The company has ongoing strategic interest and engagement with potential partners.
- Dataworks operates two large-scale Centralised Self-Exclusion platforms in Australia and Ontario.
- The financial outlook for the company is strong, with continued growth expected in regulated gambling technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anagenics Limited (AN1) ORDINARY FULLY PAID |
Consumer Staple |
$6 |
Appendix 4C & Activity Report for Q4 FY2026
|
30 Jul 2026 10:17AM |
$0.006 |
$0.006 |
fallen by
0%
|
|
AN1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Anagenics Limited anticipates its first full-year profit for FY2026, subject to audit.
- Operating cash outflow for 4Q26 was $0.08 million.
- Reduction in payables and borrowings from $2 million to $0.2 million.
- BLC Cosmetics successfully restructured and expanding its product range.
- Royalty revenue of $446k from YSB product line in 4Q26.
- Total YSB royalty revenue of $1.3 million for the year ending 30 June 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Zenith Minerals Limited (ZNC) ORDINARY FULLY PAID |
Materials |
$57 |
Change in substantial holding from FRS
|
30 Jul 2026 10:16AM |
$0.090 |
$0.089 |
fallen by
1.11%
|
|
| Forrestania Resources Limited (FRS) ORDINARY FULLY PAID |
Materials |
$640 |
Change in substantial holding for ZNC
|
30 Jul 2026 10:16AM |
$0.355 |
$0.395 |
risen by
11.27%
|
|
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$17 |
Quarterly Activities & Cashflow Report - June 2026 (Q4FY26)
|
30 Jul 2026 10:12AM |
$0.009 |
$0.008 |
fallen by
11.11%
|
|
LIT - Price-sensitive ASX Announcement
Full Release
Key Points
- Envirostream achieved revenue of A$1.65 million in Q4 FY26.
- Gross profit for the quarter was A$0.64 million, with a gross margin of 39%.
- Livium formalized a recycling services framework with CATL.
- The company launched a Share Purchase Plan to secure funding.
- A strategic alliance and investment discussions are ongoing with a multinational organization.
- Livium completed the relocation of its operations to the Derrimut Hub.
- The company seeks to become cash neutral through cost management and growth in recycling revenues.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$17 |
Proposed issue of securities - LIT
|
30 Jul 2026 10:07AM |
$0.009 |
$0.008 |
fallen by
11.11%
|
|
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$17 |
Proposed issue of securities - LIT
|
30 Jul 2026 10:06AM |
$0.009 |
$0.008 |
fallen by
11.11%
|
|
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$17 |
LIT Secures Initial A$1.575m Institutional Investment & SPP
|
30 Jul 2026 10:06AM |
$0.009 |
$0.008 |
fallen by
11.11%
|
|
LIT - Price-sensitive ASX Announcement
Full Release
Key Points
- Livium secures A$1.575 million initial investment from Lind.
- Potential funding capacity up to A$11.75 million.
- Launch of Share Purchase Plan for additional shareholder investment.
- Funding supports battery recycling and working capital.
- Strategic evaluation of financing options undertaken.
- Funding agreements are unsecured and interest-free.
- Focus on operational efficiency and new recycling opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Jayride Group Limited (JAY) ORDINARY FULLY PAID |
Industrials |
$9 |
Director Appointment/Resignation
|
30 Jul 2026 10:04AM |
$0.006 |
$0.006 |
fallen by
0%
|
|
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$171 |
June 2026 Quarterly activity report & Appendix 4C
|
30 Jul 2026 10:03AM |
$0.039 |
$0.046 |
risen by
17.95%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Pivotal XanaMIA phase 2b/3 Alzheimer's disease trial on track for final results in November 2026
- 88% of main trial participants continue in open-label extension phase with Xanamem therapy
- Positive scientific advice from European Medicines Agency aligns with US FDA
- New patents received for Xanamem treatment and manufacturing
- June 2026 cash balance of $16.7 million extends runway beyond trial results to mid-2027
- Continued strong enrolment and progress in XanaMIA trial and open-label extension
- Publication of positive anti-depressant activity of Xanamem in the British Journal of Psychiatry
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kinetiko Energy Limited (KKO) ORDINARY FULLY PAID |
Energy |
$61 |
Proposed issue of securities - KKO
|
30 Jul 2026 10:03AM |
$0.035 |
$0.039 |
risen by
10%
|
|
| Kinetiko Energy Limited (KKO) ORDINARY FULLY PAID |
Energy |
$61 |
Completion of $5.4M Placement
|
30 Jul 2026 10:03AM |
$0.035 |
$0.039 |
risen by
10%
|
|
KKO - Price-sensitive ASX Announcement
Full Release
Key Points
- Kinetiko Energy Ltd completed a $5.4M placement.
- The placement price was $0.03 per share, a 14% discount.
- Major shareholder Talent 10 Holdings committed $3M.
- Funds will support Phase 1 development and exploration.
- The placement was structured in two tranches, pending shareholder approval.
- Tranche 1 involves 50 million shares, Tranche 2 involves 130 million shares.
- Funds will assist in developing the Brakfontein gas wells aiming for commercial production in 2027.
- Kinetiko plans to secure a new CEO and focus on gas production permitting.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Beetaloo Energy Australia Limited (BTL) ORDINARY FULLY PAID |
Energy |
$354 |
BTL Signs Digital Development MOU with Halliburton
|
30 Jul 2026 10:03AM |
$0.220 |
$0.235 |
risen by
6.82%
|
|
| Kingsland Minerals Ltd (KNG) ORDINARY FULLY PAID |
Materials |
$6 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jul 2026 10:03AM |
$0.069 |
$0.062 |
fallen by
10.14%
|
|
KNG - Price-sensitive ASX Announcement
Full Release
Key Points
- Completed soil sampling at Lake Johnston confirming lithium anomalies.
- High gallium recovery rate at Leliyn Graphite Project.
- Received R&D tax refund of $809,000 post-quarter end.
- End of quarter cash balance at $458,000.
- Continued focus on exploration in Northern Territory and Western Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$3,117 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jul 2026 10:01AM |
$2.010 |
$2.400 |
risen by
19.40%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Ryoncil® net revenue was US$36 million for the quarter.
- Full-year Ryoncil® revenue was US$115 million.
- Net operating cash spend was US$43.8 million for the full year.
- US$103 million of cash held at June 30, 2026.
- Drew US$50 million from a five-year facility to clear debts.
- Expanding Ryoncil® use to adults with SR-aGvHD.
- Achieved target of 300 patients treated in a Phase 3 trial for chronic low back pain.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
